← Back to Clinical Trials
Recruiting NCT07475936

NCT07475936 Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07475936
Status Recruiting
Phase
Sponsor First Affiliated Hospital of Guangxi Medical University
Condition Acute Ischemic Stroke
Study Type OBSERVATIONAL
Enrollment 392 participants
Start Date 2026-03-22
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 80 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)Standard medical care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 392 participants in total. It began in 2026-03-22 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The benefit of intravenous tenecteplase in very old patients with acute ischemic stroke (AIS) remain uncertain. This real-world study aims to evaluate the effectiveness and safety of intravenous tenecteplase in AIS patients aged 80 years or older within 4.5 hours of symptom onset.

Eligibility Criteria

Inclusion Criteria: 1. Age \> 80 years; 2. Clinically diagnosed with acute ischemic stroke and arrived at the hospital within 4.5 hours of symptom onset; 3. Informed consent signed by the patient or legally authorized representative. Exclusion Criteria: 1. Any contraindication to intravenous thrombolysis (excluding age); 2. Previous treatment with other thrombolytic agents such as alteplase, urokinase, plasminogen activator, or reteplase; 3. Current participation in other interventional studies; 4. The investigator deems the patient unsuitable for this study or the study might pose significant risk to the patient (e.g., due to psychiatric disorders, cognitive or emotional impairments that prevent understanding or adherence to study procedures and/or follow-up).

Contact & Investigator

Central Contact

Dong Pan, MD, PhD

✉ dongpan012@hotmail.com

📞 86-156 2648 3251

Principal Investigator

Yuan Wu, MD, PhD

PRINCIPAL INVESTIGATOR

First Affiliated Hospital of Guangxi Medical University

Frequently Asked Questions

Who can join the NCT07475936 clinical trial?

This trial is open to participants of all sexes, aged 80 Years or older, studying Acute Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07475936 currently recruiting?

Yes, NCT07475936 is actively recruiting participants. Contact the research team at dongpan012@hotmail.com for enrollment information.

Where is the NCT07475936 trial being conducted?

This trial is being conducted at Nanning, China.

Who is sponsoring the NCT07475936 clinical trial?

NCT07475936 is sponsored by First Affiliated Hospital of Guangxi Medical University. The principal investigator is Yuan Wu, MD, PhD at First Affiliated Hospital of Guangxi Medical University. The trial plans to enroll 392 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology